Oragenics (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, announced that its Chief Medical Officer Dr James Kelly has been appointed to the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury and Brain Health. The appointment reflects Dr Kelly’s pioneering work, including his previous leadership at the National Intrepid Center of Excellence at Walter Reed National Military Medical Center, and reinforces the foundation’s mission to support research, raise awareness and drive actionable solutions for brain injury care. Janet Huffman, Interim Chief Executive Officer and Chief Financial Officer of Oragenics, noted the move bolsters the company’s commitment to developing its novel intranasal treatment for concussion, ONP-002, while Leigh Steinberg welcomed Dr Kelly’s expertise in transforming concussion treatment. Dr Kelly said he is honored to join the Medical Board and dedicated to advancing innovative treatment options to improve patient outcomes.
To view the full press release, visit https://ibn.fm/33LVs
About Oragenics
Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (“mTBI”), also known as concussion, and for treating Niemann Pick Disease Type C (“NPC”), as well as proprietary powder formulation and an intranasal delivery device. For more information, visit the company’s website at www.Oragenics.com
NOTE TO INVESTORS: The latest news and updates relating to OGEN are available in the company’s newsroom at https://ibn.fm/OGEN
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]
InvestorWire is powered by IBN